A Proposed Methodology to Select Radioisotopes for Use in Radionuclide Therapy

References

1. 1.↵
   1. Jensen ME,
   2. Evans AJ,
   3. Mathis JM,
   4. et al

   . Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral body compression fractures: technical aspects. AJNR Am J Neuroradiol 1997;18:1897–904

   Abstract
2. 2.↵
   1. Jensen ME,
   2. McGraw JK,
   3. Cardella JF,
   4. et al

   . Position statement on percutaneous vertebral augmentation: a consensus statement developed by the American Society of Interventional and Therapeutic Neuroradiology, Society of Interventional Radiology, American Association of Neurological Surgeons/Congress of Neurological Surgeons, and American Society of Spine Radiology. AJNR Am J Neuroradiol 2007;28:1439–43

   FREE Full Text
3. 3.↵
   1. Hirsch AE,
   2. Medich DC,
   3. Rosenstein BS,
   4. et al

   . Radioisotopes and vertebral augmentation: dosimetric analysis of a novel approach for the treatment of malignant compression fractures. Radiother Oncol 2008;87:119–26. Epub 2008 Feb 7

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Larson SM,
   2. Krenning EP

   . A pragmatic perspective on molecular targeted radionuclide therapy. J Nucl Med 2005;46(suppl 1):1S–3S

   FREE Full Text
5. 5.↵
   1. Delclos L

   . Are interstitial radium applications passé? Front Radiat Ther Oncol 1978;12:42–56
6. 6.↵
   1. Schaeflein JW,
   2. Schlesinger T,
   3. Stephens SO,
   4. et al

   . Some observations on iridium 192. Front Radiat Ther Oncol 1978;12:13–20
7. 7.↵
   1. Allen BJ,
   2. Raja C,
   3. Rizvi S,
   4. et al

   . Targeted alpha therapy for cancer. Phys Med Biol 2004;49:3703–12

   CrossRefPubMed
8. 8.↵
   1. Allen BJ

   . Clinical trials of targeted alpha therapy for cancer. Rev Recent Clin Trials 2008;3:185–91

   CrossRefPubMed
9. 9.↵
   1. Rosenkranz AA,
   2. Vaidyanathan G,
   3. Pozzi OR,
   4. et al

   . Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At. Int J Radiat Oncol Biol Phys 2008;72:193–200

   PubMed
10. 10.↵
    1. Song H,
    2. Shahverdi K,
    3. Huso DL,
    4. et al

    . 213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model. Cancer Res 2008;68:3873–80

    Abstract/FREE Full Text
11. 11.↵
    1. Serafini AN,
    2. Houston SJ,
    3. Resche I,
    4. et al

    . Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998;16:1574–81

    Abstract/FREE Full Text
12. 12.↵
    American National Standards Institute, Inc. ANSI/HPS N43.6–2007. Sealed Radioactive Sources-Classification. Health Physics Society, 2007. Available at: http://www.hps.org/hpssc/documents/standards_Order_Form1.pdf. Accessed October 24, 2008
13. 13.↵
    1. Fischer H,
    2. Aiginger H,
    3. Havlik E,
    4. et al

    . Radionuclidic purity aspects of 153Sm for radionuclide therapy. Presented at: International Congress of the International Radiation Protection Agency, Madrid, Spain, May 23–28, 2004
14. 14.↵
    1. Uusijärvi H,
    2. Bernhardt P,
    3. Ericsson T,
    4. et al

    . Dosimetric characterization of radionuclides for systemic tumor therapy: influence of particle range, photon emission, and subcellular distribution. Med Phys 2006;33:3260–69

    CrossRefPubMed
15. 15.↵
    1. Hall E,
    2. Giaccia AJ

    . Radiobiology for the Radiologist. 6th ed. Philadelphia: Lippincott Wilkins & Williams; 2006
16. 16.↵
    1. Setlow P

    . Spores of Bacillus subtilis: their resistance to and killing by radiation, heat and chemicals. J Appl Microbiol 2006;101:514–25, 2006

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Atcher RW,
    2. Friedman AM,
    3. Hines JJ

    . An improved generator for the production of 212Pb and 212Bi from 224Ra. Int J Rad Appl Instrum A 1988;39:283–86

    CrossRefPubMed
18. 18.↵
    1. Larsen RH,
    2. Wieland BW,
    3. Zalutsky MR

    . Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (alpha,2n)211 at reaction. Appl Radiat Isot 1996;47:135–43

    CrossRefPubMed
19. 19.↵
    1. Tolmachev V,
    2. Carlsson J,
    3. Lundqvist H

    . A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy: availability of suitable radionuclides. Acta Oncol 2004;43:264–75

    CrossRefPubMed
20. 20.↵
    1. Lindegren S,
    2. Bäck T,
    3. Jensen HJ

    . Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields. Appl Radiat Isot 2001;55:157–60

    CrossRefPubMed
21. 21.↵
    1. Minar E,
    2. Pokrajac B,
    3. Ahmadi R,
    4. et al

    . Brachytherapy for prophylaxis of restenosis after long-segment femoropopliteal angioplasty: pilot study. Radiology 1998;208:173–79

    PubMedWeb of Science
22. 22.↵
    1. Ricke J,
    2. Wust P,
    3. Wieners G,
    4. et al

    . CT-guided interstitial single-fraction brachytherapy of lung tumors: phase I results of a novel technique. Chest 2006;127:2237–42

    CrossRef
23. 23.↵
    1. Zhang FJ,
    2. Wu PH,
    3. Zhao M,
    4. et al

    . CT guided radioactive seed 125I implantation in treatment of pancreatic cancer [in Chinese]. Zhonghua Yi Xue Za Zhi 2006;86:223–27

    PubMed
24. 24.↵
    1. Zhang FJ,
    2. Li CX,
    3. Wu PH,
    4. et al

    . Radioactive seed 125I implantation in treating recurrence and metastasis after liver transplantation in hepatoma [in Chinese]. Zhonghua Yi Xue Za Zhi 2007;87:956–59

    PubMed
25. 25.↵
    1. Zhang FJ,
    2. Li CX,
    3. Wu PH,
    4. et al

    . CT guided radioactive 125I seed implantation in treating localized advanced pulmonary carcinoma [in Chinese]. Zhonghua Yi Xue Za Zhi 2007;87:3272–75

    PubMed
26. 26.↵
    1. Jiang Y,
    2. Huang ZL,
    3. Wu PH,
    4. et al

    . Short-term efficacy of CT-guided radioactive seed 125I implantation on residual or relapsing metastatic lymph nodes in advanced tumor patients after multi-modality treatment [in Chinese]. Ai Zheng 2008;27:1082–87

    PubMed
27. 27.↵
    1. Zhang L,
    2. Fan WJ,
    3. Huang JH,
    4. et al

    . CT guided 125I seeds implantation in treatment of local recurrent rectal cancer after surgery resection: analysis of 21 cases [in Chinese]. Zhonghua Yi Xue Za Zhi 2008;88:1335–38

    PubMed
28. 28.↵
    1. Zhang JQ,
    2. Huang XQ,
    3. Zhang J,
    4. et al

    . CT guided radioactive seed (125)I implantation in treating multiple bone metastasis [in Chinese]. Zhonghua Yi Xue Za Zhi 2008;88:2739–42

    PubMed
29. 29.↵
    1. Andrews JC,
    2. Walker SC,
    3. Ackermann RJ,
    4. et al

    . Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 1994;35:1637–44

    Abstract/FREE Full Text
30. 30.↵
    1. Grady ED

    . Internal radiation therapy of hepatic cancer. Dis Colon Rectum 1979;22:371–75

    CrossRefPubMed
31. 31.↵
    1. Ariel IM,
    2. Pack GT

    . Treatment of inoperable cancer of the liver by intra-arterial radioactive isotopes and chemotherapy. Cancer 1967;20:793–804

    CrossRefPubMed
32. 32.↵
    1. Mantravadi RV,
    2. Spigos DG,
    3. Tan WS,
    4. et al

    . Intraarterial yttrium 90 in the treatment of hepatic malignancy. Radiology 1982;142:783–86

    PubMed
33. 33.↵
    1. Feinendegen LE

    . Microdosimetric considerations of hepatic radioembolization. J Nucl Med 1994;35:1644–46

    FREE Full Text
34. 34.↵
    1. Ibrahim SM,
    2. Lewandowski RJ,
    3. Sato KT,
    4. et al

    . Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol 2008;14:1664–69

    CrossRefPubMedWeb of Science